Literature DB >> 24140636

Determination of HSV-1 UL5 and UL29 gene copy numbers in an HSV complementing Vero cell line.

Ali Azizi1, Francisca Aidoo, Lucy Gisonni-Lex, Bryan McNeil.   

Abstract

The genetic stability of transgenes is a critical characteristic used to assess constructed cell lines used for vaccine production. The evaluation of gene copy numbers by a qPCR method, is one of the most common approaches used to assess the consistency of transgenes in a constructed cell line. The cell line AV529-19 is a Vero-based cell line specifically engineered to express the HSV-1 UL5 and UL29 open reading frames. AV529-19 is used to support the replication of a defective HSV-2 viral candidate vaccine called HSV529. To assess the genetic stability of the UL5 and UL29 transgenes in AV529-19 cells, a digital PCR-based approach was developed. During characterization of the test method, the specificity, accuracy, and intermediate precision of the assay was investigated based on regulatory guidelines. The developed assay was used to monitor the stability of the transgenes in the manufactured AV529-19 cell lines by comparison of transgene copy numbers in the master cell bank (MCB) with their copy numbers in the extended cell bank (ECB). Results showed that the UL29 and UL5 transgenes are stable in that there are one and three copies of the UL29 and UL5 genes, respectively, per cell in both the AV529-19 MCB and ECB.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Digital PCR; ECB; Gene copy number; HSV; MCB; Vaccine; Vero cells; dPCR; digital PCR; extended cell bank; master cell bank

Mesh:

Substances:

Year:  2013        PMID: 24140636     DOI: 10.1016/j.jbiotec.2013.10.002

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  1 in total

Review 1.  New approaches for characterization of the genetic stability of vaccine cell lines.

Authors:  Siemon Ng; Lucy Gisonni-Lex; Ali Azizi
Journal:  Hum Vaccin Immunother       Date:  2017-02-23       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.